Standard therapy or additionally radioactive iodine (131I) therapy; which will stop the recurrence of glioblastoma multiforme (GBM)?
Endokrynol Pol. 2024 Apr 22. doi: 10.5603/ep.98240. Online ahead of print.ABSTRACTGlioblastoma multiforme (GBM) is the most aggressive malignant brain tumour. The average survival time for a patient diagnosed with GBM, using standard treatment methods, is several months. Authors of the article pose a direct question: Is it possible to treat GBM solely with radioactive iodine (¹³¹I) therapy without employing the sodium iodide symporter (NIS) gene? After all, NIS has been detected not only in the thyroid but also in various tumours. The main author of this article (A.C.), with the assistance of her colleagues (physicians ...
Source: Endokrynologia Polska - April 22, 2024 Category: Endocrinology Authors: Agata Czarnywojtek Pawe ł Gut Kamil Dyrka Jerzy Sowi ński Nadia Sawicka-Gutaj Katarzyna Katulska Piotr Stajgis Mateusz Wykr ętowicz Jakub Moskal Jeremi Ko ściński Krzysztof Pietro ńczyk Patryk Graczyk Maciej Robert Krawczy ński Ewa Florek Ewelina S Source Type: research
Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia
CONCLUSIONS: Genotyping of ABCB1, ABCG2, and CYP3A5 genes may be considered in the management of patients with CML to tailor therapy and optimize clinical outcomes.PMID:38640718 | DOI:10.1016/j.intimp.2024.112090 (Source: International Immunopharmacology)
Source: International Immunopharmacology - April 19, 2024 Category: Allergy & Immunology Authors: Fang Cheng Zheng Cui Qiang Li Shi Chen Weiming Li Yu Zhang Source Type: research
Duodenal gastrointestinal stromal tumor presenting with life ‐threatening upper GI bleeding in a young patient: A case report and literature review
We present a case of a 31-year-old male patient presented with massive active hemateme sis and melena with hemorrhagic shock. The patient presented with massive hematemesis and melena of 1 h duration. Endoscopy showed pulsating active bleeding from the third part of the duodenum which was difficult to manage via endoscopy. Histopathologic evaluation showed spindle cell type GIST. In traoperatively, there was a nodular mass with active bleeding on the third part of the duodenum. Duodenectomy with end-to-end anastomosis was done. Discharged with no postoperative complication and was put on imatinib. There are considerable ...
Source: Clinical Case Reports - April 18, 2024 Category: General Medicine Authors: Samuel Addisu Abera,
Amanuel Kassa Tadesse,
Kirubel Addisu Abera,
Kassa Berie Zegeye,
Mohammed Alemu Ibrahim,
Ashenafi Amsalu Feleke,
Cheru lilay Gebrehiwet,
Segenet Bizuneh Mengistu,
Hirut Tesfahun Alemu,
Yohannis Derbew Molla Tags: CASE REPORT Source Type: research
Adjuvant therapy for rare rectal gastrointestinal stromal tumors: A case report
Key Clinical MessageAnorectal gastrointestinal stromal tumors are extremely rare, constituting less than 0.1% of rectal tumors. Surgical resection using a transanal wide excision followed by adjuvant therapy with tyrosine kinase inhibitors can be a successful treatment combination to remove the mass and prevent recurrence while preserving the integrity of the anal sphincter.AbstractGastrointestinal stromal tumors (GISTs) are a rare subset of neoplasms, accounting for about 1% –2% of primary gastrointestinal malignancies. The stomach is the most common site for GISTs, with anorectal GISTs being exceptionally rare, represe...
Source: Clinical Case Reports - April 17, 2024 Category: General Medicine Authors: Ting ‐Yi Chu,
Ta‐Wei Pu,
Chao‐Yang Chen Tags: CASE REPORT Source Type: research
GSE263645 Whole transcriptome sequencing for wild type and IRAIN over-expression K562 cells
Series Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe development of tyrosine kinase inhibitors (TKIs) has revolutionarily increased the overall survival of patients with chronic myeloid leukemia (CML). However, drug resistance remains a major obstacle. Here, we demonstrated that a BCR-ABL1-independent long non-coding RNA, IRAIN, is constitutively expressed at low levels in CML, resulting in imatinib resistance. IRAIN knockdown decreased the sensitivity of CD34+ CML blasts and cell lines to imatinib, whereas IRAIN overexpression significantly increased sensitivity. Mechanistically, IRAI...
Source: GEO: Gene Expression Omnibus - April 13, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
ConclusionThe results of imatinib plus RIF as a first-line treatment of CP-CML compared with imatinib might be more effective for achieving a deeper molecular response (Chinadrugtrials number, CTR20170221). (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - April 11, 2024 Category: Cancer & Oncology Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferati...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferati...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human
Vascul Pharmacol. 2024 Apr 8;155:107371. doi: 10.1016/j.vph.2024.107371. Online ahead of print.ABSTRACTAn effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI2 agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiprolife...
Source: Vascular Pharmacology - April 10, 2024 Category: Drugs & Pharmacology Authors: Daniel Morales-Cano Bianca Barreira Mar ía Callejo Miguel A Olivencia Antonio Ferruelo Javier Milara Jos é Ángel Lorente Laura Moreno Ángel Cogolludo Francisco Perez-Vizcaino Source Type: research
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group
This study investigated changes in treatment modalities and outcomes of chronic myeloid leukemia in the chronic phase (CP-CML) after the approval of second-generation tyrosine kinase inhibitors (2G-TKIs) for first-line therapy. Patients were grouped into those who underwent TKI therapy up to December 2010 (imatinib era group, n = 185) and after January 2011 (2G-TKI era group, n = 425). All patients in the imatinib era group were initially treated with imatinib, whereas patients in the 2G-TKI era group were mostly treated with dasatinib (55%) or nilotinib (36%). However, outcomes including progression-free survival, overall...
Source: International Journal of Hematology - April 8, 2024 Category: Hematology Authors: Noriyoshi Iriyama Eisaku Iwanaga Yuta Kimura Naoki Watanabe Maho Ishikawa Hitomi Nakayama Eriko Sato Takayuki Tabayashi Toru Mitsumori Tomoiku Takaku Tomonori Nakazato Michihide Tokuhira Hiroyuki Fujita Miki Ando Yoshihiro Hatta Tatsuya Kawaguchi Source Type: research
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group
This study investigated changes in treatment modalities and outcomes of chronic myeloid leukemia in the chronic phase (CP-CML) after the approval of second-generation tyrosine kinase inhibitors (2G-TKIs) for first-line therapy. Patients were grouped into those who underwent TKI therapy up to December 2010 (imatinib era group, n = 185) and after January 2011 (2G-TKI era group, n = 425). All patients in the imatinib era group were initially treated with imatinib, whereas patients in the 2G-TKI era group were mostly treated with dasatinib (55%) or nilotinib (36%). However, outcomes including progression-free survival, overall...
Source: International Journal of Hematology - April 8, 2024 Category: Hematology Authors: Noriyoshi Iriyama Eisaku Iwanaga Yuta Kimura Naoki Watanabe Maho Ishikawa Hitomi Nakayama Eriko Sato Takayuki Tabayashi Toru Mitsumori Tomoiku Takaku Tomonori Nakazato Michihide Tokuhira Hiroyuki Fujita Miki Ando Yoshihiro Hatta Tatsuya Kawaguchi Source Type: research
